Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 25;4(12):bvaa140. doi: 10.1210/jendso/bvaa140

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Proportion of patients with reported (A) pain and (B) visual symptoms in those who were and were not currently being treated with systemic glucocorticoids. *Indicates a significant difference from patients not treated with a systemic glucocorticoid (P ≤ 0.04). ^†Indicates a significant difference from patients currently being treated with oral glucocorticoids (P ≤ 0.027). Ocular/orbital pain represents pain in the primary gaze, pain with eye movement, and/or photophobia. Decreased vision represents a decrease in visual acuity, blurry vision, and/or vision loss.